SHR-2004

Phase 3Small molecule

BBeijing Suncadia Pharmaceuticals Co., Ltd

SHR-2004 is one of 85 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

Total Knee ArthroplastyActive, not recruiting

Atrial FibrillationActive, not recruiting

Venous ThromboembolismPhase 2

Active, not recruiting

Total Knee ArthroplastyPhase 3

Active, not recruiting

Atrial FibrillationPhase 1

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

SHR-2004

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 3

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 10

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Total Knee Arthroplasty

NCT06825416

Clinical

Trials by Indication[1]

Total Knee Arthroplasty2 trials

A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Active, not recruiting·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 3·NCT06825416·1,166 enrolled

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Completed·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2·NCT05752461·353 enrolled

Atrial Fibrillation1 trial

Study on the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2004 Injection in Adult Patients With Atrial Fibrillation

Unknown status·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 1·NCT06280768·48 enrolled

Venous Thromboembolism1 trial

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Completed·BBeijing Suncadia Pharmaceuticals Co., Ltd·Phase 2·NCT06220123·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SHR-2004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-2004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-2004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Suncadia Pharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Suncadia Pharmaceuticals Co., Ltd

SHR-2004

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Total Knee Arthroplasty2 trials

Atrial Fibrillation1 trial

Venous Thromboembolism1 trial

References

Drug Info

Quick Facts

Related News